Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation

被引:11
作者
Coi, Alessio [1 ]
Massarelli, Ilaria [2 ]
Testai, Lara [3 ]
Calderone, Vincenzo [3 ]
Bianucci, Anna Maria [1 ]
机构
[1] Univ Pisa, Dipartimento Sci Farmaceut, I-56126 Pisa, Italy
[2] Univ Pisa, Dipartimento Chim & Chim Ind, I-56126 Pisa, Italy
[3] Univ Pisa, Dipartimento Psichiatria Neurobiol Farmacol & Bio, I-56126 Pisa, Italy
关键词
hERG K+ channel; Toxicophore; QT interval prolongation; Molecular modeling; Homology building;
D O I
10.1016/j.ejmech.2007.12.025
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Drugs delaying cardiac repolarization by blockade of hERG K+ channel generally prolong the QT interval of the electrocardiogram, an effect regarded as a cardiac risk factor with the potential to cause 'torsade des pointes'-type arrhythmias in humans. The present study applied a homology building technique and molecular dynamics simulations to model the pore of hERG K+ channel. A docking analysis was then performed on selected ligands which were classified as QT-prolonging or non-prolonging after experimental measurements in in vivo anesthetized guinea pig. The results of this structural analysis provided a "toxicophoric" model that was further exploited to inspect a dataset of known QT-prolonging/non-prolonging molecules. The emerging major chemical features to be avoided, in order to obtain cardiac safe therapeutic agents, comprise the simultaneous presence of (i) a protonated nitrogen atom within an observed range of distances from a heteroatom; (ii) aromatic groups capable of interacting within an area defined by Gly657 residues of the pore or within an area located at the top of the longitudinal axis of the pore. Moreover, additional hydrophobic moieties interacting with one of the equatorial cavities located in the area near-by Tyr652 residues and/or with a hydrophobic fing defined by Phe656 residues should be avoided. (C) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:2479 / 2488
页数:10
相关论文
共 50 条
[21]   Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig [J].
Fossa, AA ;
Wisialowski, T ;
Wolfgang, E ;
Wang, E ;
Avery, M ;
Raunig, DL ;
Fermini, B .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 486 (02) :209-221
[22]   Exploring structural features of the interaction between the scorpion ToxinCnErg1 and ERG K+ channels [J].
Frénal, K ;
Xu, CQ ;
Wolff, N ;
Wecker, K ;
Gurrola, GB ;
Zhu, SY ;
Chi, CW ;
Possani, LD ;
Tytgat, J ;
Delepierre, M .
PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2004, 56 (02) :367-375
[23]   Parametrized models of aqueous free energies of solvation based on pairwise descreening of solute atomic charges from a dielectric medium [J].
Hawkins, GD ;
Cramer, CJ ;
Truhlar, DG .
JOURNAL OF PHYSICAL CHEMISTRY, 1996, 100 (51) :19824-19839
[24]   PAIRWISE SOLUTE DESCREENING OF SOLUTE CHARGES FROM A DIELECTRIC MEDIUM [J].
HAWKINS, GD ;
CRAMER, CJ ;
TRUHLAR, DG .
CHEMICAL PHYSICS LETTERS, 1995, 246 (1-2) :122-129
[25]  
*INS, 1995, BIOSYM MSI
[26]   Influence of opioid agonists on cardiac human ether-a-go-go related gene K+ currents [J].
Katchman, AN ;
McGroary, KA ;
Kilborn, MJ ;
Kornick, CA ;
Manfredi, PL ;
Woosley, RL ;
Ebert, SN .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 303 (02) :688-694
[27]  
Kirsch Glenn E., 2004, Journal of Pharmacological and Toxicological Methods, V50, P93, DOI 10.1016/j.vascn.2004.06.003
[28]   A structural basis for drug-induced long QT syndrome [J].
Mitcheson, JS ;
Chen, J ;
Lin, M ;
Culberson, C ;
Sanguinetti, MC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) :12329-12333
[29]   Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization [J].
Moreno, I ;
Caballero, R ;
González, T ;
Arias, C ;
Valenzuela, C ;
Iriepa, I ;
Gálvez, E ;
Tamargo, J ;
Delpón, E .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 304 (02) :862-873
[30]   Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine [J].
Paul, AA ;
Witchel, HJ ;
Hancox, JC .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 136 (05) :717-729